var title_f6_24_6528="Arsenical skin lesions";
var content_f6_24_6528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arsenical skin lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient shows multiple skin lesions associated with arsenic including hyperkeratosis, suspected Bowen's disease, and nonhealing ulcers (suspected cancer).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Chakroborti, D, Mukherjee, SC, Pati, S, et al. Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger? Environ Health Perspect 2003; 111:1194.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6528=[""].join("\n");
var outline_f6_24_6528=null;
var title_f6_24_6529="Lateral luxation";
var content_f6_24_6529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral luxation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tooth is displaced laterally. The periodontal ligament is lacerated and fracture of the supporting bone occurs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6529=[""].join("\n");
var outline_f6_24_6529=null;
var title_f6_24_6530="Patient information: Cryptosporidiosis (The Basics)";
var content_f6_24_6530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83627\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cryptosporidiosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cryptosporidiosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H115033203\">",
"      <span class=\"h1\">",
"       What is cryptosporidiosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cryptosporidiosis is an infection of the digestive system (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). It can cause diarrhea, nausea, and stomach ache.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115033217\">",
"      <span class=\"h1\">",
"       What are the symptoms of cryptosporidiosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cryptosporidiosis does not always cause symptoms. It is caused by a parasite. Some people carry the parasite without knowing it.",
"     </p>",
"     <p>",
"      When symptoms do happen, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        Feeling sick",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Loss of appetite",
"       </li>",
"       <li>",
"        Belly cramps",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with conditions that weaken the body&rsquo;s infection-fighting system can get sicker from cryptosporidiosis. This includes people with HIV and AIDS. The body&rsquo;s infection-fighting system is also called the &ldquo;immune system.&rdquo; People with weak immune systems have a hard time fighting infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115033231\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends. See your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have severe diarrhea (4 or more runny or watery bowel movements in 1 day)",
"       </li>",
"       <li>",
"        Have severe belly pain",
"       </li>",
"       <li>",
"        Cannot eat or drink",
"       </li>",
"       <li>",
"        Have a fever higher than 100.4&deg;F (38&deg;C)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Young children and older adults with symptoms should make sure to see their doctor or nurse. That&rsquo;s because they can get dehydrated more easily than other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115033246\">",
"      <span class=\"h1\">",
"       How does cryptosporidiosis spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The parasite that causes cryptosporidiosis lives in bowel movements from infected people and animals. It can spread through:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Water &mdash; The parasite can live in drinking water systems or swimming pools. People can get infected when they swallow water that has the parasite in it.",
"       </li>",
"       <li>",
"        Touching infected people &mdash; Someone who has the infection can spread it if he or she does not wash his or her hands after a bowel movement. Or a baby who is infected can have the parasite in his or her diaper from a bowel movement. You can get sick if you change the baby&rsquo;s diaper and do not wash your hands afterwards.",
"       </li>",
"       <li>",
"        Animals &ndash; A person can get the infection from touching an infected animal. Children are more likely to get infected this way. That&rsquo;s because children are more likely to touch animals and not wash their hands afterwards.",
"       </li>",
"       <li>",
"        Food &mdash; Food that has the parasite in it can make a person sick. But cooking the food can kill the parasite.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115033261\">",
"      <span class=\"h1\">",
"       Is there a test for cryptosporidiosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have it, he or she will ask you for a sample of your bowel movement. The sample can be tested for cryptosporidiosis and other infections that can cause the same symptoms.",
"     </p>",
"     <p>",
"      Doctors can also use samples of other body fluids or tissue to look for the parasite. But these samples might not be needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115033276\">",
"      <span class=\"h1\">",
"       How is cryptosporidiosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends. Most adults get better in about 2 weeks without treatment.",
"     </p>",
"     <p>",
"      Doctors can give children a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?5/3/5172?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      (brand name: Alinia&reg;). That&rsquo;s because cryptosporidiosis can make children sicker than adults. The medicine helps stop diarrhea and keep the infection from spreading.",
"     </p>",
"     <p>",
"      People with HIV should also get treatment for cryptosporidiosis. That&rsquo;s because the infection can last a long time in people who have weak immune systems. Getting treatment for cryptosporidiosis helps to shorten the symptoms. People with HIV who are not taking HIV medicines need to start taking them. The HIV medicines boost the immune system. This helps get rid of the infection.",
"     </p>",
"     <p>",
"      People who have severe diarrhea might need treatment in the hospital. Doctors can give medicines to help stop diarrhea. They can also give fluids through an &ldquo;IV.&rdquo; This is a thin tube that goes into a vein. It can help put fluids back in the body if a person loses too much water from diarrhea.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115033291\">",
"      <span class=\"h1\">",
"       Can cryptosporidiosis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower your chances of getting cryptosporidiosis by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Washing your hands after going to the bathroom or changing diapers.",
"       </li>",
"       <li>",
"        Throwing away dirty diapers and animal bowel movements in a closed garbage can away from where you cook and eat.",
"       </li>",
"       <li>",
"        NOT drinking water from streams, lakes, or public swimming pools.",
"       </li>",
"       <li>",
"        Wearing disposable gloves when handling bowel movements from pets &ndash; Wash your hands well when you are done, even if you were wearing gloves.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you get sick, you can keep from spreading cryptosporidiosis to other people by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Staying home from work or school until you feel better.",
"       </li>",
"       <li>",
"        NOT swimming in a public pool until your diarrhea has been gone for 2 weeks.",
"       </li>",
"       <li>",
"        Handling food safely - Tips include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        NOT drinking unpasteurized milk or foods made with it",
"       </li>",
"       <li>",
"        Washing fruits and vegetables well before eating them",
"       </li>",
"       <li>",
"        Washing hands, knives, and cutting boards after they touch raw food",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115033306\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      Patient information: Dehydration (The Basics)",
"     </p>",
"     <p>",
"      Patient information: Diarrhea in adults (The Basics)",
"     </p>",
"     <p>",
"      Patient information: Diarrhea in children (The Basics)",
"     </p>",
"     <p>",
"      Patient information: Food poisoning (The Basics)",
"     </p>",
"     <p>",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </p>",
"     <p>",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </p>",
"     <p>",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/24/6530?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83627 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6530=[""].join("\n");
var outline_f6_24_6530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033203\">",
"      What is cryptosporidiosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033217\">",
"      What are the symptoms of cryptosporidiosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033231\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033246\">",
"      How does cryptosporidiosis spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033261\">",
"      Is there a test for cryptosporidiosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033276\">",
"      How is cryptosporidiosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033291\">",
"      Can cryptosporidiosis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115033306\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83627\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_24_6531="HSV primary";
var content_f6_24_6531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary genital herpes simplex infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6531=[""].join("\n");
var outline_f6_24_6531=null;
var title_f6_24_6532="Closure of vaginal cuff";
var content_f6_24_6532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Closure of vaginal cuff during abdominal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    0 or 2-0 gauge synthetic absorbable figure of eight stitches are used to close the vaginal cuff. The suture incorporates the uterosacral and cardinal ligaments at the angle of the vagina.",
"    <br>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6532=[""].join("\n");
var outline_f6_24_6532=null;
var title_f6_24_6533="Pericarditis in renal failure";
var content_f6_24_6533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pericarditis in renal failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6533/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6533/contributors\">",
"     Robert M Black, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6533/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6533/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6533/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6533/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/24/6533/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with end-stage renal disease may develop pericardial disease, including pericarditis and pericardial effusions, and occasionally chronic constrictive pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Advances in management have decreased the incidence of pericarditis in patients with renal failure, but this problem is still associated with significant morbidity and occasional mortality. Two forms of pericarditis in renal failure have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Uremic pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic pericarditis results from inflammation of the visceral and parietal membranes of the pericardial sac. There is a correlation with the degree of azotemia (the BUN is usually &gt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [22",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    although the pathogenesis is poorly understood. Except in the case of systemic immune disorders (such as lupus erythematosus or scleroderma), there is no relationship with the underlying cause of renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dialysis-associated pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis is occasionally observed in patients on maintenance hemodialysis or peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/3\">",
"     3",
"    </a>",
"    ]. At least two factors may contribute to this problem: inadequate dialysis (ie, the patient has uremic pericarditis)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid overload [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the two forms of uremic pericarditis can be distinguished by the type (serous versus hemorrhagic) of effusion that is present, but there is significant overlap. Pathologic examination of the pericardium typically shows adhesions between the pericardial membranes, which are thicker than normal. Loculated bloody fluid when present is due in part to the frequent impairment in platelet function in renal failure and the use of anticoagulation during hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of pericarditis in renal failure are similar to those observed with other causes. Most patients complain of fever and pleuritic chest pain, the intensity of which is quite variable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/1\">",
"     1",
"    </a>",
"    ]. The pain is characteristically worse in the recumbent position. A pericardial rub is generally audible, but is frequently transient. Signs of cardiac tamponade may be seen, particularly in patients with rapid pericardial fluid accumulation. However, the high prevalence of autonomic impairment in this patient population may hinder the normally observed rise in heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/5\">",
"     5",
"    </a>",
"    ]. Moreover, some patients with uremic pericarditis present without symptoms or suggestive findings (chest pain or pericardial rub) on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/6\">",
"     6",
"    </a>",
"    ]. Cardiac ultrasonography reveals a pericardial effusion in at least 50 percent of cases. A concomitant pleural effusion, which is commonly exudative, may be observed, findings consistent with generalized serositis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some individuals, uremic pericarditis may be associated with worsening anemia. This is a presumed reflection of the inflammatory state inducing resistance to erythropoiesis-stimulating agents (ESAs)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/8\">",
"     8",
"    </a>",
"    ]; however, volume overload with hemodilution may also be present.",
"   </p>",
"   <p>",
"    There is one unusual feature of uremic pericarditis: the electrocardiogram does not show the typical diffuse ST and T wave elevations observed with other causes of acute pericarditis. This results from the lack of penetration of the inflammatory cells into the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/5\">",
"     5",
"    </a>",
"    ]. Hypothyroidism is the other condition where pericarditis may be observed without ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the finding of these electrocardiographic abnormalities suggests some other cause for the pericarditis, such as intercurrent infection. With the development of cardiac tamponade, typical ECG changes (eg, electrical alternans) may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of otherwise unexplained pericarditis in a patient with advanced renal failure is an indication to institute dialysis (providing there is no circulatory compromise or evidence of impending tamponade). Most patients with uremic pericarditis respond rapidly to dialysis with resolution of chest pain as well as a decrease in the size of the pericardial effusion.",
"   </p>",
"   <p>",
"    Either hemodialysis or peritoneal dialysis can be used, but each technique has certain disadvantages. Since anticoagulation can increase hemorrhage into the pericardial space, systemic anticoagulation should be avoided when hemodialysis is the chosen modality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .) In addition, acute fluid removal with hemodialysis can lead to cardiovascular collapse in patients with tamponade or pretamponade. Peritoneal dialysis, on the other hand, can compromise respiratory function due to intraperitoneal fluid accumulation. The form of dialytic therapy is usually determined by local availability and the long term plans for the patient with chronic end-stage renal disease.",
"   </p>",
"   <p>",
"    Management is often more complicated in patients with dialysis-associated pericarditis. The intensity of dialysis is usually increased in hemodynamically stable patients with no or small to medium-sized effusions. Increased dialysis usually leads to resolution of the pericarditis within one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/11\">",
"     11",
"    </a>",
"    ]. The size of the pericardial effusion should be monitored throughout this period by serial cardiac ultrasonography. At times, a patient on hemodialysis may be switched to peritoneal dialysis to avoid heparinization if heparin-free dialysis cannot be performed.",
"   </p>",
"   <p>",
"    The uses of antiinflammatory medications and systemic corticosteroids have been tried with limited success when intensive dialysis is ineffective.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    can reduce the fever, but does not accelerate resolution of the pericardial inflammation or effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/12\">",
"     12",
"    </a>",
"    ]. High-dose corticosteroids may be beneficial, but their systemic use is limited by their potential side-effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/13\">",
"     13",
"    </a>",
"    ] and by a potentially higher risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/14\">",
"     14",
"    </a>",
"    ]. By comparison,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    may reduce recurrences in patients with uremic pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, drainage of a large effusion is the treatment of choice if it fails to improve in 7 to 14 days with intensified dialysis or if it increases in size. Drainage is imperative without a trial of intensive hemodialysis in patients presenting with a large when there is evidence of diastolic collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of procedure utilized is determined by local experience and by the condition of the patient. Acute cardiac tamponade with circulatory collapse should be treated with pericardiocentesis, preferably under echocardiographic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While pericardiocentesis may not be recommended for effusions that do not produce circulatory compromise, the rapidity with which the effusion develops may affect this decision. Since the pericardial space may accommodate slowly developing effusions, pericardiocentesis may be recommended with only a moderate-sized effusion that develops rapidly, even without evidence of tamponade. The morbidity and potential mortality (due, for example, to right ventricular laceration) in this setting are not insignificant but can be substantially reduced by echocardiographic guidance.",
"   </p>",
"   <p>",
"    The surgical procedures for a large, nonresolving effusion are subxiphoid pericardiotomy (with or without the instillation of intrapericardial corticosteroids) or pericardiectomy. The indications for the selection of one approach over the other are not uniformly established. Subxiphoid pericardiotomy, which can be performed under local anesthesia, has the additional advantages of relatively few complications and a high success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. An intrapericardial catheter can also be placed for drainage and steroid instillation (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide 50 mg every six hours for two to three days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pericardiectomy, in contrast, is a definitive procedure that is only rarely associated with recurrent pericarditis or effusion. Nevertheless, there is potential morbidity associated with the procedure, which must be performed under general anesthesia and through a thoracotomy approach. As a result, it is usually recommended only in settings in which pericardiotomy cannot be performed or has been unsuccessful. An alternative to open thoracotomy is thoracoscopic pericardiectomy, which may successful in selected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with acute renal failure-associated hemorrhagic pericarditis and tamponade, transient constrictive-like pericarditis may develop after pericardiocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/21\">",
"     21",
"    </a>",
"    ]. This finding usually resolves completely over time, although chronic constrictive pericarditis has been described in ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pericarditis following renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis has been reported in patients after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/23\">",
"     23",
"    </a>",
"    ]. It usually develops within two months after transplant surgery; uremia is the most common cause with cytomegalovirus and other infections being next in frequency. The diagnosis is usually suggested by the finding of a pericardial friction rub on physical examination; it can be confirmed by echocardiography. Pericardiocentesis may be required for diagnosis or treatment in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/23\">",
"     23",
"    </a>",
"    ]. While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been associated with pericarditis, this typically occurs after heart, rather than renal, transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    has been associated in rare circumstances with pericardial effusions among renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6533/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639797\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with end-stage renal disease may develop pericarditis and pericardial effusions, and less commonly, chronic constrictive pericarditis. Two forms of pericarditis in renal failure have been described including uremic and dialysis-associated. Pericarditis has also been reported in patients after renal transplantation and is usually related to uremia or, less commonly, cytomegalovirus or other infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pericarditis following renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uremic pericarditis results from inflammation of the visceral and parietal membranes of the pericardial sac. Uremic pericarditis correlates with the degree of azotemia, but, except in the case of systemic immune disorders (such as lupus erythematosus or scleroderma), there is no relationship with the underlying cause of renal failure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Uremic pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis-associated pericarditis is occasionally seen in patients on maintenance hemodialysis or chronic peritoneal dialysis. Contributing factors include inadequate dialysis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluid overload. Anemia has also been associated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dialysis-associated pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of pericarditis in renal failure are similar to those observed with other causes. Most patients complain of fever and pleuritic chest pain that is worse in the recumbent position. A pericardial rub is often audible, but frequently transient. Signs of cardiac tamponade may be seen, although autonomic impairment may hinder the normally observed rise in heart rate. Some patients have no symptoms or signs on physical examination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dialysis-associated pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac ultrasonography reveals a pericardial effusion in at least 50 percent of cases of renal failure-associated pericarditis. A pleural effusion may be observed. The electrocardiogram does not show the typical diffuse ST and T wave elevations that are observed with other causes of acute pericarditis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dialysis-associated pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of uremic or dialysis-associated pericarditis is the initiation or intensification of dialysis, providing there is no circulatory compromise or evidence of impending tamponade. Most patients respond to dialysis with resolution of chest pain and a decrease in the pericardial effusion. Either hemodialysis or peritoneal dialysis can be used. The size of the pericardial effusion should be monitored by serial cardiac ultrasonography. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic anticoagulation should be avoided in patients with uremic or dialysis-associated pericarditis. Patients on hemodialysis may be switched to peritoneal dialysis to avoid heparinization if heparin-free hemodialysis cannot be performed. Significant fluid removal with hemodialysis can lead to cardiovascular collapse in patients with tamponade or pretamponade. Peritoneal dialysis can compromise respiratory function due to intraperitoneal fluid accumulation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drainage is the treatment of choice for large effusions that fail to improve or increase in size despite initiation or intensification of dialysis. Drainage is imperative for patients who present with large effusions and evidence of diastolic collapse. Pericardiocentesis may also be recommended for those with moderate-sized effusions that develop rapidly, even without evidence of tamponade. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The surgical procedures for large, nonresolving effusions include subxiphoid pericardiotomy (with or without the instillation of intrapericardial corticosteroids) or pericardiectomy. An intrapericardial catheter can also be placed for drainage and steroid instillation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/1\">",
"      Alpert MA, Ravenscraft MD. Pericardial involvement in end-stage renal disease. Am J Med Sci 2003; 325:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/2\">",
"      Maisch B, Seferovi PM, Risti AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/3\">",
"      Rutsky EA, Rostand SG. Treatment of uremic pericarditis and pericardial effusion. Am J Kidney Dis 1987; 10:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/4\">",
"      Lundin, AP. Recurrent uremic pericarditis: A marker of inadequate dialysis. Semin Dial 1990; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/5\">",
"      Gunukula SR, Spodick DH. Pericardial disease in renal patients. Semin Nephrol 2001; 21:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/6\">",
"      Banerjee A, Davenport A. Changing patterns of pericardial disease in patients with end-stage renal disease. Hemodial Int 2006; 10:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/7\">",
"      Bakirci T, Sasak G, Ozturk S, et al. Pleural effusion in long-term hemodialysis patients. Transplant Proc 2007; 39:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/8\">",
"      Tarng DC, Huang TP. Uraemic pericarditis: a reversible inflammatory state of resistance to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1997; 12:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/9\">",
"      Kudo Y, Yamasaki F, Doi T, et al. Clinical significance of low voltage in asymptomatic patients with pericardial effusion free of heart disease. Chest 2003; 124:2064.",
"     </a>",
"    </li>",
"    <li>",
"     Nicholls, AJ. Heart and Circulation. In: Handbook of Dialysis, Daugirdas, JT, Ing, TS (Eds), Little, Brown and Co., New York 1994. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/11\">",
"      Tseng JR, Lee MJ, Yen KC, et al. Course and outcome of dialysis pericarditis in diabetic patients treated with maintenance hemodialysis. Kidney Blood Press Res 2009; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/12\">",
"      Spector D, Alfred H, Siedlecki M, Briefel G. A controlled study of the effect of indomethacin in uremic pericarditis. Kidney Int 1983; 24:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/13\">",
"      Iyoda M, Ajiro Y, Sato K, et al. A case of refractory uremic pleuropericarditis--successful corticosteroid treatment. Clin Nephrol 2006; 65:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/14\">",
"      Shabetai R. Corticosteroids for recurrent pericarditis: on the road to evidence-based medicine. Circulation 2008; 118:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/15\">",
"      Spaia S, Patsalas S, Agelou A, et al. Managing refractory uraemic pericarditis with colchicine. Nephrol Dial Transplant 2004; 19:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/16\">",
"      Ifudu O. Daily dialysis in hemodialysis patients with pericardial effusion: where are the data? Int J Artif Organs 1999; 22:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/17\">",
"      Spodick DH. Acute cardiac tamponade. N Engl J Med 2003; 349:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/18\">",
"      Wood JE, Mahnensmith RL. Pericarditis associated with renal failure: evolution and management. Semin Dial 2001; 14:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/19\">",
"      Buselmeier TJ, Davin TD, Simmons RL, et al. Treatment of intractable uremic pericardial effusion. Avoidance of pericardiectomy with local steroid instillation. JAMA 1978; 240:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/20\">",
"      Nakamoto H, Suzuki T, Sugahara S, et al. Successful use of thoracoscopic pericardiectomy in elderly patients with massive pericardial effusion caused by uremic pericarditis. Am J Kidney Dis 2001; 37:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/21\">",
"      Zakynthinos E, Theodorakopoulou M, Daniil Z, et al. Hemorrhagic cardiac tamponade in critically ill patients with acute renal failure. Heart Lung 2004; 33:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/22\">",
"      Kleynberg RL, Kleynberg VM, Kleynberg LM, et al. Chronic constrictive pericarditis in association with end-stage renal disease. Int J Nephrol 2011; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/23\">",
"      Sever MS, Steinmuller DR, Hayes JM, et al. Pericarditis following renal transplantation. Transplantation 1991; 51:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/24\">",
"      Hastillo A, Thompson JA, Lower RR, et al. Cyclosporine-induced pericardial effusion after cardiac transplantation. Am J Cardiol 1987; 59:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6533/abstract/25\">",
"      Steele GH, Adamkovic AB, Demopoulos LA, et al. Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database. Transplantation 2008; 85:645.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1940 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6533=[""].join("\n");
var outline_f6_24_6533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H639797\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Uremic pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dialysis-associated pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pericarditis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H639797\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_24_6534="Hemopneumothorax II PA";
var content_f6_24_6534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of hemopneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemopneumothorax after gunshot wound to the left hemithorax. Supine chest radiograph shows left pleural effusion, small left inferolateral pneumothorax, left lung contusion, and marked cardiomediastinal shift to the right. A right pneumothorax is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6534=[""].join("\n");
var outline_f6_24_6534=null;
var title_f6_24_6535="Mucous membrane pemphigoid vaginal";
var content_f6_24_6535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions are present on the genital mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6535=[""].join("\n");
var outline_f6_24_6535=null;
var title_f6_24_6536="Mechanisms of commotio cordis";
var content_f6_24_6536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Mechanisms of commotio cordis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Link MS, Estes NA. Athletes and arrhythmis. J Cardiovasc Electrophysiol 2010; 21:1184. Copyright &copy; 2010. Reproduced with permission of John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6536=[""].join("\n");
var outline_f6_24_6536=null;
var title_f6_24_6537="Treatment of myoclonus";
var content_f6_24_6537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of myoclonus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6537/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6537/contributors\">",
"     John N Caviness, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6537/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6537/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6537/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/24/6537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus is a clinical sign characterized by sudden, brief, shock-like, involuntary movements caused by muscular contractions or inhibitions. Muscular contractions produce \"positive myoclonus,\" whereas muscular inhibitions produce \"negative myoclonus\" or asterixis. Myoclonic movements have many possible etiologies, anatomic sources, and pathophysiologic features. Treatment is generally guided by the anatomic and physiologic classification of the myoclonus in question.",
"   </p>",
"   <p>",
"    This topic will review the treatment of myoclonus. The treatment of myoclonic epilepsy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H7#H7\">",
"     \"Epilepsy syndromes in children\", section on 'Absence seizures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H5#H5\">",
"     \"Epilepsy syndromes in children\", section on 'Myoclonic epilepsy of infancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H15#H15\">",
"     \"Epilepsy syndromes in children\", section on 'Juvenile myoclonic epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other clinical aspects of myoclonus are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link\">",
"     \"Classification and evaluation of myoclonus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link\">",
"     \"Symptomatic (secondary) myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of myoclonus is important because it is helpful to guide treatment choices for the many different types of myoclonus. The classification of myoclonus is reviewed here briefly, and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link\">",
"     \"Classification and evaluation of myoclonus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link\">",
"     \"Symptomatic (secondary) myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most useful scheme for therapeutic decisions classifies myoclonus by the localization of the physiologic mechanism that generates it (",
"    <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"     table 1",
"    </a>",
"    ). These anatomic-physiologic categories (along with important examples) are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cortical myoclonus (eg, posthypoxic myoclonus, progressive myoclonus epilepsy and progressive myoclonus ataxia syndromes, most cases of toxic-metabolic myoclonus, myoclonus associated with neurodegenerative disease, and myoclonus associated with Creutzfeldt-Jakob disease)",
"     </li>",
"     <li>",
"      Cortical-subcortical myoclonus (eg, juvenile myoclonic epilepsy)",
"     </li>",
"     <li>",
"      Subcortical-nonsegmental myoclonus (eg, myoclonus-dystonia syndrome)",
"     </li>",
"     <li>",
"      Segmental myoclonus (eg, palatal myoclonus)",
"     </li>",
"     <li>",
"      Peripheral myoclonus (eg, hemifacial spasm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to providing guidance for treatment, this classification paradigm is useful for localization of the underlying lesion and for the diagnosis of certain disorders that have a characteristic myoclonus physiology.",
"   </p>",
"   <p>",
"    Another scheme classifies myoclonus into four broad clinical-etiologic categories as follows (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physiologic",
"     </li>",
"     <li>",
"      Essential",
"     </li>",
"     <li>",
"      Epileptic",
"     </li>",
"     <li>",
"      Symptomatic (secondary)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these categories contains myoclonus arising from various specific etiologies and pathophysiologic mechanisms. Thus, differentiation by clinical-etiologic category is not always pure.",
"   </p>",
"   <p>",
"    The ideal way to control myoclonus is to treat the underlying disorder, as this may partly or totally reverse certain types of myoclonus. Examples include myoclonus caused by an acquired abnormal metabolic state, a removable medication or toxin, an excisable lesion, or a psychogenic etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With most types of myoclonus, however, treatment of the underlying disorder is impossible or ineffective. In these cases, symptomatic treatment is justified if the myoclonus is disabling. Unfortunately, there is sparse evidence from controlled clinical trials to direct myoclonus therapy, in part because no drug has been designed or marketed specifically for the purpose of treating myoclonus. Nearly all of the evidence comes from observational case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the limited available data regarding the treatment of individual etiologies of myoclonus (",
"    <a class=\"graphic graphic_table graphicRef78331 \" href=\"UTD.htm?20/60/21455\">",
"     table 2",
"    </a>",
"    ), our approach to symptomatic therapy is guided mainly by the underlying physiologic classification of the myoclonus (",
"    <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification and evaluation of myoclonus\", section on 'Anatomic and physiologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This strategy is based upon the premise that an agent or treatment that is effective for one type of myoclonus is likely to be effective for other causes of myoclonus that share the same underlying physiologic mechanism. Furthermore, an agent or treatment that is effective for one physiologic type of myoclonus may be less effective or ineffective for another physiologic type, or may even cause worsening.",
"   </p>",
"   <p>",
"    Some clinical phenotypes of myoclonus have more than one potential physiologic mechanism. In cases when the myoclonus physiologic classification cannot be determined, presuming the myoclonus physiology that usually occurs in that diagnosis is a reasonable way to proceed. As examples, a cortical myoclonus physiology may be presumed in a child with Unverricht-Lundborg disease confirmed by genetic testing (EPM1 mutation) and in an adult with Creutzfeldt-Jakob disease who cannot cooperate with electrophysiology testing.",
"   </p>",
"   <p>",
"    When both the specific etiology and myoclonus physiology are uncertain, treatments that have evidence of effectiveness for cortical myoclonus can be tried first, since a cortical physiology is the most common mechanism for myoclonus. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cortical myoclonus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Myoclonus treatment is often unsuccessful from the viewpoint of the patient. High expectations for a marked decrease or total elimination of myoclonus are usually unrealistic. In addition, multiple medication trials are sometimes necessary to find the best drug or drug combination to control myoclonus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of medications, mainly anticonvulsants, have been used to treat myoclonus, but few have been evaluated in rigorous clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Levetiracetam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no randomized controlled trials are available, there is limited evidence from small open-label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], case series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/6-9\">",
"     6-9",
"    </a>",
"    ], and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/10-13\">",
"     10-13",
"    </a>",
"    ] that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    is effective or partially effective for various causes of cortical myoclonus. Patients treated in these studies included those with progressive myoclonic epilepsy and progressive myoclonic ataxia syndromes (due to Unverricht-Lundborg disease, Lafora disease, and myoclonus epilepsy with red ragged fibers), benign adult familial myoclonic epilepsy, asterixis (ie, negative myoclonus), posthypoxic myoclonus, and Creutzfeldt-Jakob disease.",
"   </p>",
"   <p>",
"    The best-designed of these uncontrolled studies was an open-label evaluation of add-on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    (mean dose 3214 mg daily after titration phase) for the treatment of chronic refractory cortical myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/5\">",
"     5",
"    </a>",
"    ]. Compared with the pretreatment phase, all 14 patients who completed the study had significant improvement in myoclonus, as assessed by the Unified Myoclonus Rating Scale (UMRS). However, there was no significant change in the negative myoclonus (asterixis) scores of the UMRS.",
"   </p>",
"   <p>",
"    In one report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    was beneficial for three patients with spinal myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    is initiated at 500 to 1000 mg daily given in two divided doses. It can be titrated up by 1000 mg every two weeks as needed, up to 3000 mg daily. If well tolerated and response is suboptimal, a maximum daily dose of 4000 mg can be tried. Therapeutic levetiracetam doses for myoclonus usually range between 1000 mg to 3000 mg daily.",
"   </p>",
"   <p>",
"    The most common adverse events associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    are fatigue, somnolence, dizziness, and infection (upper respiratory). Most adverse events are mild to moderate in intensity and typically occur during the initial titration phase (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"UTD.htm?2/17/2334\">",
"     table 3A-B",
"    </a>",
"    ). Abrupt withdrawal of levetiracetam may precipitate seizures or worsening of myoclonus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Piracetam",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few small controlled studies have found that piracetam (not available in the United States) is beneficial for cortical myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. As an example, a six-week randomized double-blind crossover trial involving 20 adults with Unverricht-Lundborg disease, a cause of progressive myoclonic ataxia, reported that the highest dose of piracetam (24 g daily given in two divided doses) was significantly more effective than placebo for improvement in the primary outcome measure (the mean sum score of six components of a myoclonus rating scale) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/17\">",
"     17",
"    </a>",
"    ]. The improvement was considered clinically relevant. Lower doses of piracetam (16.8 and 9.6 g daily) were associated with a nonsignificant improvement in the primary outcome measure.",
"   </p>",
"   <p>",
"    Piracetam is usually started at 2.4 g daily, given in three divided doses. Therapeutic doses of piracetam range between 2.4 g to 24 g daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Abrupt discontinuation of piracetam should be avoided since it may precipitate myoclonus exacerbation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clonazepam",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    for cortical myoclonus is supported by data from uncontrolled observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    may also be helpful for subcortical-nonsegmental types of myoclonus, including essential myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/21\">",
"     21",
"    </a>",
"    ], myoclonus-dystonia, reticular reflex myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/20\">",
"     20",
"    </a>",
"    ], hyperekplexia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/22\">",
"     22",
"    </a>",
"    ], and propriospinal myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    was beneficial for essential palatal myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/24\">",
"     24",
"    </a>",
"    ], a type that has a segmental physiology. Clonazepam is considered a first-line agent for the treatment of spinal segmental myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/20,25\">",
"     20,25",
"    </a>",
"    ], but often results in only partial improvement when there is an effect.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    is typically started at 0.5 mg daily and gradually increased to a total daily dose of 1.5 to 3 mg given in three divided doses. Clonazepam doses as high as 15 mg daily are often necessary but should be introduced slowly.",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    are drowsiness, dizziness, fatigue, and sedation. These can sometimes be ameliorated by adjusting the dose. Abrupt reductions or withdrawals of clonazepam can cause both an exacerbation of myoclonus and withdrawal seizures. As with other benzodiazepines, clonazepam may produce physical and psychological dependence. In addition, tolerance with loss of effectiveness may develop over a period of several months in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Valproic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from uncontrolled observational studies suggests that valproic acid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) is effective for various types of cortical myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/2,19,20,26\">",
"     2,19,20,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a few case reports, valproic acid treatment was associated with improvement in palatal myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Valproic acid is introduced slowly, starting at 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in three divided doses. It may be increased by 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day every week as needed. Therapeutic doses are typically in the range of 1200 to 2000 mg daily.",
"   </p>",
"   <p>",
"    During initial treatment with valproic acid, transient gastrointestinal upset may occur, sometimes with nausea and vomiting, and less often with abdominal pain and diarrhea. Other side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    include weight gain, obesity, hair loss, easy bruising, and tremor (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"UTD.htm?2/17/2334\">",
"     table 3A-B",
"    </a>",
"    ). Rare side effects include agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure,",
"    <span class=\"nowrap\">",
"     dermatitis/rash,",
"    </span>",
"    serum sickness, and pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Botulinum toxin injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin injections of the levator veli palatini",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tensor veli palatini have been effective in some cases of essential palatal myoclonus, a form of segmental myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In the largest case series, botulinum toxin injections were associated with complete resolution of symptoms (objective, intrusive clicking tinnitus) in four of five treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/31\">",
"     31",
"    </a>",
"    ]. One patient had transient side effects that included dysphagia and nasal speech.",
"   </p>",
"   <p>",
"    There are a few reports of some success with botulinum toxin injections for the pain and movements of spinal segmental myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An evidence-based review published in 2008 by the American Academy of Neurology concluded that botulinum toxin injections are possibly effective for hemifacial spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/34\">",
"     34",
"    </a>",
"    ], a form of peripheral myoclonus.",
"   </p>",
"   <p>",
"    In a randomized controlled trial, 11 patients with hemifacial spasm were randomly cycled through four treatment arms, which consisted of three different doses of botulinum toxin injection and one saline placebo injection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/35\">",
"     35",
"    </a>",
"    ]. There was objective improvement in symptoms after 84 percent of botulinum toxin injections versus 0 percent of placebo injections. Facial weakness was an expected side effect and was observed after 97 percent of botulinum toxin injections. Facial bruising, diplopia, and ptosis occurred after 20, 13, and 7 percent of injections, respectively.",
"   </p>",
"   <p>",
"    In another small trial, the mean duration of benefit after botulinum toxin injection for hemifacial spasm was 16.5 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/36\">",
"     36",
"    </a>",
"    ]. Retrospective evidence suggests that regular botulinum toxin injections for hemifacial spasm are beneficial and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of peripheral myoclonus may also respond to botulinum toxin injections [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23711555\">",
"    <span class=\"h2\">",
"     Intrathecal baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    has been tried in a single case of posthypoxic myoclonus that was refractory to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/40\">",
"     40",
"    </a>",
"    ]. At doses of 75 to 105 micrograms per hour, both the resting and action myoclonus was controlled. In another report, two cases of spinal myoclonus had marked response to this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/41\">",
"     41",
"    </a>",
"    ]. Further examples are needed for verification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not considered first-line agents, limited evidence suggests a number of other drugs are occasionally useful for myoclonus of various physiologic types, including [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       Baclofen",
"      </a>",
"      for palatal myoclonus",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"       Benztropine",
"      </a>",
"      for essential myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      for cortical, segmental, and peripheral types of myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       Diazepam",
"      </a>",
"      for spinal segmental myoclonus",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      for cortical, cortical-subcortical, and segmental types of myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       Phenobarbital",
"      </a>",
"      for cortical myoclonus",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"       Primidone",
"      </a>",
"      for cortical myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       Sumatriptan",
"      </a>",
"      for palatal myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/24,46\">",
"       24,46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/31/32246?source=see_link\">",
"       Tetrabenazine",
"      </a>",
"      for spinal segmental myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      for spinal segmental myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"       Trihexyphenidyl",
"      </a>",
"      for essential myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       Zonisamide",
"      </a>",
"      for cortical types of myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/49,50\">",
"       49,50",
"      </a>",
"      ] and for propriospinal myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/51\">",
"       51",
"      </a>",
"      ], a type of subcortical-nonsegmental myoclonus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    has also been used for cortical myoclonus. However, phenytoin may exacerbate myoclonus in some patients, particularly those with Unverricht-Lundborg disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/52\">",
"     52",
"    </a>",
"    ] or segmental myoclonus (palatal myoclonus). It may also worsen myoclonic seizures (cortical-subcortical myoclonus).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     Sodium oxybate",
"    </a>",
"    , the sodium salt form of gamma hydroxybutyrate, has been used for cortical myoclonus and myoclonus-dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/53\">",
"     53",
"    </a>",
"    ]. However, sodium oxybate is a restricted drug in the United States that is approved only for the treatment of cataplexy associated with narcolepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data regarding surgical interventions for myoclonus are even more limited than the data for pharmacologic treatments.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case report, a patient with posthypoxic myoclonus, a type of cortical myoclonus, responded to chronic motor cortex stimulation using an implanted electrode strip placed epidurally via a burr hole [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are reports of success with deep brain stimulation (DBS) of the thalamus or globus pallidus for myoclonus-dystonia syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/55-59\">",
"       55-59",
"      </a>",
"      ], a subtype of essential myoclonus with subcortical-nonsegmental physiology. One of the largest evaluated 10 patients with essential myoclonus, and reported that DBS was associated with a significant decrease in both myoclonus and dystonia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/58\">",
"       58",
"      </a>",
"      ]. There was benefit with stimulation of both the internal globus pallidus and ventral intermediate thalamic nucleus, although stimulation of the ventral intermediate thalamic nucleus was associated with more adverse effects. Further studies confirming benefit are needed before DBS can be recommended for this condition.",
"     </li>",
"     <li>",
"      Tensor veli palatini tenotomy and occlusion of the Eustachian tube have been tried with variable success for treatment of essential palatal myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/60\">",
"       60",
"      </a>",
"      ]. Middle ear myoclonus has been treated with tensor tympani",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stapedius tenotomy as well as placement of ventilation tubes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/61-64\">",
"       61-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Microvascular decompression may be beneficial for hemifacial spasm. In a retrospective review of 5685 patients treated with microvascular decompression for hemifacial spasm, there was complete resolution of symptoms over a median three-year follow up in 91 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/65\">",
"       65",
"      </a>",
"      ]. Complications included transient facial palsy in 10 percent, permanent facial palsy in 1 percent, permanent hearing loss in 2 percent, and stroke and death in &lt;0.1 percent each.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHOOSING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, with the exception of two small short-term randomized controlled trials that evaluated piracetam [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/15,17\">",
"     15,17",
"    </a>",
"    ], and one small placebo-controlled trial that evaluated botulinum toxin injection&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/35\">",
"     35",
"    </a>",
"    ], the evidence base for the treatment of myoclonus consists mainly of observational case series and case reports. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pharmacologic therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Surgical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment choices are discussed here according to the physiologic type of myoclonus (",
"    <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cortical myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cortical myoclonus, drug treatment is primarily aimed at augmenting deficient inhibitory processes within the sensorimotor cortex (",
"    <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    , piracetam,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    and valproic acid are the four agents considered most effective. No trials have compared these drugs head-to-head for the treatment of myoclonus. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Levetiracetam'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Piracetam'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Clonazepam'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Valproic acid'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    and piracetam are related drugs that are generally well tolerated. Because of their relatively favorable side effect profile, we suggest using either levetiracetam or piracetam (where available) as initial therapy for patients with debilitating cortical myoclonus.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    and valproic acid are reasonable alternatives or can be considered as add-on therapy. The choice among these medications depends in part upon drug availability, physician familiarity, and patient preference.",
"   </p>",
"   <p>",
"    Many patients gain adequate relief from myoclonus only when drugs are used in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/19\">",
"     19",
"    </a>",
"    ]. Any of these four agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , piracetam, valproic acid, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ) can be used as add-on treatment. However, levetiracetam and piracetam should not be used together.",
"   </p>",
"   <p>",
"    Gait disturbance tends to be the feature of myoclonus that is most resistant to treatment. A bouncy unsteady gait with frequent falls may persist despite better control of action and reflex myoclonus in the upper limbs. In addition, there is no consistent evidence that any of the available agents are beneficial for negative myoclonus (asterixis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cortical-subcortical myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myoclonus in primary generalized epilepsies falls under the cortical-subcortical physiologic classification (",
"    <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/66\">",
"     66",
"    </a>",
"    ]. The treatment of these disorders is discussed separately in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link\">",
"     \"Epilepsy syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subcortical-nonsegmental myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard antiepileptic treatments are usually not helpful in most types of subcortical-nonsegmental myoclonus (",
"    <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"     table 1",
"    </a>",
"    ). In addition, there is an increased risk of alcoholism in patients with essential myoclonus (including myoclonus-dystonia) because the condition is ethanol-responsive.",
"   </p>",
"   <p>",
"    We suggest initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    for patients with subcortical-nonsegmental myoclonus physiology who have essential myoclonus, myoclonus-dystonia syndrome, reticular reflex myoclonus, hyperekplexia, or propriospinal myoclonus. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clonazepam'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"     Benztropine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    are alternate choices for initial or add-on therapy for patients with essential myoclonus, including myoclonus-dystonia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     Zonisamide",
"    </a>",
"    is an alternate choice as initial or add-on therapy for patients with propriospinal myoclonus. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Other drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In children, the opsoclonus-myoclonus syndrome may occur with a neuroblastoma, whereas the adult form is sometimes associated with small cell lung cancer or breast cancer. Options for treating opsoclonus-myoclonus syndrome in children and adults are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=see_link\">",
"     \"Opsoclonus myoclonus ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Segmental myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common types of segmental myoclonus are palatal myoclonus and segmental spinal myoclonus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palatal myoclonus is difficult to treat [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/67\">",
"       67",
"      </a>",
"      ]. We suggest botulinum toxin injections as initial treatment for debilitating palatal myoclonus, provided that the injections are performed by a practitioner (often an otolaryngologist) or center with sufficient expertise in the anatomic area. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Botulinum toxin injections'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other pharmacologic interventions for palatal myoclonus generally provide only limited benefit, or more commonly no benefit. However, the list of possibly useful drugs for this condition includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      , piracetam, valproic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clonazepam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Piracetam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Valproic acid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Other drugs'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because the ear clicking associated with palatal myoclonus is so disabling, surgical treatments including tensor veli palatini tenotomy and occlusion of the Eustachian tube can be considered for patients refractory to pharmacologic therapy (including botulinum toxin injection). Surgical interventions for middle ear myoclonus include tensor tympani",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stapedius tenotomy and placement of ventilation tubes. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      (up to 6 mg daily) for patients with spinal segmental myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6537/abstract/67\">",
"       67",
"      </a>",
"      ]. However, benefit is often limited. Alternative choices include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      , botulinum toxin injection,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clonazepam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Levetiracetam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Botulinum toxin injections'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Other drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Peripheral myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest botulinum toxin injection treatment for patients with hemifacial spasm and other types of peripheral myoclonus when it can be performed by physicians with expertise in this technique. Microvascular decompression is another option for patients with severe hemifacial spasm. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Botulinum toxin injections'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Surgical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other kinds of pharmacologic therapy for peripheral myoclonus are usually unsatisfactory, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    may have some effect. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Other drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2754?source=see_link\">",
"       \"Patient information: Myoclonus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain types of myoclonus can be partially or totally reversed by treating the underlying condition. Examples include myoclonus due to an acquired metabolic abnormality or an excisable lesion. However, in most cases of myoclonus, the underlying disorder cannot be treated effectively. In these situations, symptomatic treatment is justified if the myoclonus is disabling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to therapy is guided mainly by the underlying anatomic and physiologic classification of the myoclonus (",
"      <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"       table 1",
"      </a>",
"      ). These categories are (see",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cortical",
"     </li>",
"     <li>",
"      Cortical-subcortical",
"     </li>",
"     <li>",
"      Subcortical-nonsegmental",
"     </li>",
"     <li>",
"      Segmental",
"     </li>",
"     <li>",
"      Peripheral",
"     </li>",
"     <li>",
"      In cases when the etiology and myoclonus physiology are uncertain, treatments that have evidence of effectiveness for cortical myoclonus can be tried first, since a cortical physiology is the most common mechanism for myoclonus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with debilitating cortical myoclonus, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      or piracetam as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       Clonazepam",
"      </a>",
"      and valproic acid are reasonable alternatives and can also be used as add-on therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cortical myoclonus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Levetiracetam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Piracetam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Clonazepam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Valproic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The myoclonus in primary generalized epilepsies falls under the cortical-subcortical physiologic classification (",
"      <a class=\"graphic graphic_table graphicRef62397 \" href=\"UTD.htm?27/18/27948\">",
"       table 1",
"      </a>",
"      ). The treatment of these disorders is discussed separately in appropriate topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link\">",
"       \"Epilepsy syndromes in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with subcortical-nonsegmental myoclonus physiology who have essential myoclonus, myoclonus-dystonia syndrome, reticular reflex myoclonus, hyperekplexia, or propriospinal myoclonus, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"       Benztropine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"       trihexyphenidyl",
"      </a>",
"      are alternate choices as initial or add-on therapy for patients with essential myoclonus, including myoclonus-dystonia.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       Zonisamide",
"      </a>",
"      is an alternate choice as initial or add-on therapy for patients with propriospinal myoclonus. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clonazepam'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Other drugs'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Options for treating opsoclonus-myoclonus syndrome in children and adults are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=see_link\">",
"       \"Opsoclonus myoclonus ataxia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common types of segmental myoclonus are palatal myoclonus and segmental spinal myoclonus. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Segmental myoclonus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Palatal myoclonus is typically refractory to oral medications. For patients with debilitating palatal myoclonus with clicks, we suggest initial treatment with botulinum toxin injection&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Botulinum toxin injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with spinal segmental myoclonus, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      as initial treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clonazepam'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacologic therapy for peripheral myoclonus is usually unsatisfactory. For patients with disabling hemifacial spasm, we suggest treatment with botulinum toxin injection, provided that the injections are performed by a practitioner or center with the necessary anatomic and technical expertise (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Peripheral myoclonus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Botulinum toxin injections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/1\">",
"      Hinson VK, Weinstein S, Bernard B, et al. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord 2006; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/2\">",
"      Chang VC, Frucht SJ. Myoclonus. Curr Treat Options Neurol 2008; 10:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/3\">",
"      Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004; 62:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/4\">",
"      Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord 2005; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/5\">",
"      Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005; 20:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/6\">",
"      Genton P, G&eacute;lisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/7\">",
"      Krauss GL, Bergin A, Kramer RE, et al. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 56:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/8\">",
"      Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001; 57:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/9\">",
"      Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004; 45:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/10\">",
"      Gelisse P, Crespel A, Genton P, Baldy-Moulinier M. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003; 107:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/11\">",
"      Imperiale D, Bortolotto S, Cucatto A, et al. Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease. Eur Neurol 2003; 49:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/12\">",
"      Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006; 243:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/13\">",
"      Kinrions P, Ibrahim N, Murphy K, et al. Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. Neurology 2003; 60:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/14\">",
"      Keswani SC, Kossoff EH, Krauss GL, Hagerty C. Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry 2002; 73:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/15\">",
"      Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993; 8:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/16\">",
"      Ikeda A, Shibasaki H, Tashiro K, et al. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord 1996; 11:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/17\">",
"      Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998; 64:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/18\">",
"      Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001; 58:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/19\">",
"      Obeso JA, Artieda J, Rothwell JC, et al. The treatment of severe action myoclonus. Brain 1989; 112 ( Pt 3):765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/20\">",
"      Obeso JA. Therapy of myoclonus. Clin Neurosci 1995; 3:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/21\">",
"      Bressman S, Fahn S. Essential myoclonus. Adv Neurol 1986; 43:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/22\">",
"      Tijssen MA, Schoemaker HC, Edelbroek PJ, et al. The effects of clonazepam and vigabatrin in hyperekplexia. J Neurol Sci 1997; 149:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/23\">",
"      Montagna P, Provini F, Plazzi G, et al. Propriospinal myoclonus upon relaxation and drowsiness: a cause of severe insomnia. Mov Disord 1997; 12:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/24\">",
"      Fabiani G, Teive HA, S&aacute; D, et al. Palatal myoclonus: report of two cases. Arq Neuropsiquiatr 2000; 58:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/25\">",
"      Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986; 43:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/26\">",
"      Fahn S. Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 1979; 26:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/27\">",
"      Borggreve F, Hageman G. A case of idiopathic palatal myoclonus: treatment with sodium valproate. Eur Neurol 1991; 31:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/28\">",
"      Sumer M. Symptomatic palatal myoclonus: an unusual cause of respiratory difficulty. Acta Neurol Belg 2001; 101:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/29\">",
"      Bryce GE, Morrison MD. Botulinum toxin treatment of essential palatal myoclonus tinnitus. J Otolaryngol 1998; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/30\">",
"      Krause E, Leunig A, Klopstock T, G&uuml;rkov R. Treatment of essential palatal myoclonus in a 10-year-old girl with botulinum neurotoxin. Otol Neurotol 2006; 27:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/31\">",
"      Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006; 253:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/32\">",
"      Lagueny A, Tison F, Burbaud P, et al. Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A. Mov Disord 1999; 14:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/33\">",
"      Campos CR, Limongi JC, Machado FC, Brotto MW. A case of primary spinal myoclonus: clinical presentation and possible mechanisms involved. Arq Neuropsiquiatr 2003; 61:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/34\">",
"      Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/35\">",
"      Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992; 15:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/36\">",
"      Park YC, Lim JK, Lee DK, Yi SD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993; 8:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/37\">",
"      Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002; 59:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/38\">",
"      Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008; 115:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/39\">",
"      Carnero-Pardo C, S&aacute;nchez-Alvarez JC, G&oacute;mez-Camello A, et al. Myoclonus associated with thoracodorsal neuropathy. Mov Disord 1998; 13:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/40\">",
"      Birthi P, Walters C, Ortiz Vargas O, Karandikar N. The use of intrathecal baclofen therapy for myoclonus in a patient with Lance Adams syndrome. PM R 2011; 3:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/41\">",
"      Chiodo AE, Saval A. Intrathecal baclofen for the treatment of spinal myoclonus: a case series. J Spinal Cord Med 2012; 35:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/42\">",
"      Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/43\">",
"      Chokroverty S, Manocha MK, Duvoisin RC. A physiologic and pharmacologic study in anticholinergic-responsive essential myoclonus. Neurology 1987; 37:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/44\">",
"      Uluduz D, Karaali-Savrun F, Gunduz A, Kiziltan ME. An unusual case of vascular loop syndrome. J Headache Pain 2007; 8:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/45\">",
"      Nasr A, Brown N. Palatal myoclonus responding to lamotrigine. Seizure 2002; 11:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/46\">",
"      Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord 1996; 11:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/47\">",
"      Siniscalchi A, Mancuso F, Russo E, et al. Spinal myoclonus responsive to topiramate. Mov Disord 2004; 19:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/48\">",
"      Duvoisin RC. Essential myoclonus: response to anticholinergic therapy. Clin Neuropharmacol 1984; 7:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/49\">",
"      Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998; 29:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/50\">",
"      Yoshimura I, Kaneko S, Yoshimura N, Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001; 46:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/51\">",
"      Roze E, Bounolleau P, Ducreux D, et al. Propriospinal myoclonus revisited: Clinical, neurophysiologic, and neuroradiologic findings. Neurology 2009; 72:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/52\">",
"      Eldridge R, Iivanainen M, Stern R, et al. \"Baltic\" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983; 2:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/53\">",
"      Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005; 65:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/54\">",
"      Franzini A, Ferroli P, Dones I, et al. Chronic motor cortex stimulation for movement disorders: a promising perspective. Neurol Res 2003; 25:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/55\">",
"      Trottenberg T, Meissner W, Kabus C, et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001; 16:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/56\">",
"      Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004; 19:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/57\">",
"      Magari&ntilde;os-Ascone CM, Regidor I, Mart&iacute;nez-Castrillo JC, et al. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005; 76:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/58\">",
"      Gruber D, K&uuml;hn AA, Schoenecker T, et al. Pallidal and thalamic deep brain stimulation in myoclonus-dystonia. Mov Disord 2010; 25:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/59\">",
"      Azoulay-Zyss J, Roze E, Welter ML, et al. Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to &epsilon;-sarcoglycan mutations: a pilot study. Arch Neurol 2011; 68:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/60\">",
"      Ensink RJ, Vingerhoets HM, Schmidt CW, Cremers CW. Treatment for severe palatoclonus by occlusion of the eustachian tube. Otol Neurotol 2003; 24:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/61\">",
"      Bento RF, Sanchez TG, Miniti A, Tedesco-Marchesi AJ. Continuous, high-frequency objective tinnitus caused by middle ear myoclonus. Ear Nose Throat J 1998; 77:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/62\">",
"      Golz A, Fradis M, Netzer A, et al. Bilateral tinnitus due to middle-ear myoclonus. Int Tinnitus J 2003; 9:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/63\">",
"      Golz A, Fradis M, Martzu D, et al. Stapedius muscle myoclonus. Ann Otol Rhinol Laryngol 2003; 112:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/64\">",
"      Bhimrao SK, Masterson L, Baguley D. Systematic review of management strategies for middle ear myoclonus. Otolaryngol Head Neck Surg 2012; 146:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6537/abstract/65\">",
"      Miller LE, Miller VM. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg 2012; 26:438.",
"     </a>",
"    </li>",
"    <li>",
"     Caviness JN. Epileptic myoclonus. In: Atlas of Video-EEG Monitoring, Sirven JI, Stern JM (Eds), McGraw-Hill Medical, New York 2011. p.309.",
"    </li>",
"    <li>",
"     Caviness JN. Segmental myoclonus. In: Hyperkinetic Movement Disorders, Albanese A, Jankovic J (Eds), Wiley-Blackwell, Oxford 2012. p.221.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4888 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6537=[""].join("\n");
var outline_f6_24_6537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Levetiracetam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Piracetam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clonazepam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Valproic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Botulinum toxin injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23711555\">",
"      Intrathecal baclofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHOOSING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cortical myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cortical-subcortical myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subcortical-nonsegmental myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Segmental myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Peripheral myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4888|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/18/27948\" title=\"table 1\">",
"      Anatomic physiologic classification myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/60/21455\" title=\"table 2\">",
"      Clinical etiologic classification myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/28/3533\" title=\"table 3A\">",
"      Common side effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/34/30252\" title=\"table 3B\">",
"      Rare serious side effects AEDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=related_link\">",
"      Opsoclonus myoclonus ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2754?source=related_link\">",
"      Patient information: Myoclonus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_24_6538="Lamivudine monotherapy for chronic hepatitis B virus infection";
var content_f6_24_6538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lamivudine monotherapy for chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6538/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6538/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6538/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/24/6538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/24/6538/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/24/6538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main aim of treatment for chronic hepatitis B is to suppress hepatitis B virus (HBV) replication before there is irreversible liver damage. Interferon alfa was the first treatment approved in most countries. It leads to a beneficial response in 30 to 40 percent of patients, but is expensive, and may be accompanied by unpleasant side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many antiviral and immunomodulatory therapies have shown promise, and may have a key role in the treatment of chronic hepatitis B. One of these,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (Epivir-HBV), was originally used for the treatment of patients with human immunodeficiency virus infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .) It was subsequently found to be effective in inhibiting HBV replication.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    (3TC) is the (-) enantiomer of 2', 3'-dideoxy 3'-thiacytidine. It is phosphorylated to the triphosphate (3TC-TP) which competes with dCTP for incorporation into growing DNA chains, causing chain termination. This may occur during reverse transcription of the first strand of HBV DNA, and during synthesis of the second strand of HBV DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/1\">",
"     1",
"    </a>",
"    ]. Lamivudine may also reverse the T cell hyporesponsiveness to hepatitis B viral antigens observed in patients who have chronic HBV infection, although this effect appears to be transient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Lamivudine monotherapy is effective in suppressing HBV replication and in ameliorating liver disease in patients with HBeAg-positive as well as in patients with HBeAg-negative chronic hepatitis B.",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of chronic hepatitis B with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . A general approach to patients with hepatitis B (including other treatment options) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from a National Institutes of Health (NIH) workshop on the management of hepatitis B proposes that responses to antiviral therapy of chronic hepatitis B should be categorized as biochemical, virological, or histological, and as on-therapy or sustained off-therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/5\">",
"     5",
"    </a>",
"    ]. These terms will be used throughout the subsequent discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HBeAg-positive chronic hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is well tolerated and that treatment for 12 months is associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normalization of the serum alanine aminotransferase (ALT) in approximately 50 to 70 percent of patients",
"     </li>",
"     <li>",
"      HBeAg loss in approximately 30 percent of patients and HBeAg seroconversion in approximately 15 to 20 percent of patients",
"     </li>",
"     <li>",
"      Histologic improvement defined as a decrease in necroinflammatory scores by &ge;2 points in approximately 50 to 60 percent of patients",
"     </li>",
"     <li>",
"      Similar antiviral efficacy as a 16-week course of interferon monotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of HBeAg loss or seroconversion is higher with longer duration of therapy and in patients who have elevated serum aminotransferases regardless of ethnic origin. Follow-up data indicate that HBeAg seroconversion is sustained in 60 to 80 percent of patients. A problem with longer duration of therapy is the selection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant mutants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Asian patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in Asian patients was illustrated in a study that included 358 Chinese patients with chronic hepatitis B who were randomly assigned to receive placebo or lamivudine (25 or 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/6\">",
"     6",
"    </a>",
"    ]. The respective responses at the end of the one-year treatment period in these three groups were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HBeAg seroconversion in 4, 13, and 16 percent",
"     </li>",
"     <li>",
"      Normalization of serum ALT in 24, 65, and 72 percent",
"     </li>",
"     <li>",
"      Improvement in the histologic necroinflammatory score by &ge;2 in 25, 49, and 56 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up reports of 58 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    continuously for five years showed that the rate of HBeAg seroconversion at one, two, three, four, and five years were 17, 27, 33, 47, and 50 percent, respectively, indicating that HBeAg seroconversion rate increased with longer duration of treatment. However, the proportion of patients with lamivudine-resistant mutants also increased from 14 percent in year one to 38, 49, 66 and 69 percent after two, three, four, and five years of treatment, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HBeAg-negative chronic hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is also effective in patients with HBeAg negative chronic hepatitis B (most of the patients presumably have precore or core promoter HBV mutants). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=see_link\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\"",
"    </a>",
"    .) HBV DNA loss and ALT normalization were observed in 65 to 96 percent of patients by one year in several series, although relapse occurred in 48 to 90 percent of responding patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Histologic improvement was seen in approximately 60 percent of patients after 12 months of therapy.",
"   </p>",
"   <p>",
"    Breakthrough infections were usually associated with the emergence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant mutants. Breakthrough infections were associated with flares of hepatitis in some patients, and hepatic decompensation in a few patients. Extending the duration of treatment resulted in progressively lower rates of response due to the selection of lamivudine-resistant mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/12\">",
"     12",
"    </a>",
"    ]. In one study of 78 patients, virologic remission (undetectable HBV DNA by polymerase chain reaction [PCR] assay) decreased from 77 percent at 12 months to 52 percent at 24 months, and 42 percent at 36 months; the corresponding rates of biochemical remission were 90, 63, and 53 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective multicenter study evaluated clinical outcomes in relation to the virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/13\">",
"     13",
"    </a>",
"    ]. A virologic response was defined as a negative test result in the hybrid capture or the branched DNA assay",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an HBV DNA level of less than 10(5)",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    The study included a total of 656 patients who had received therapy for a median of 22 months (range 1 to 66 months). A virologic response was observed in 616 patients (95 percent) but was maintained in only 39 percent of patients after four years. In patients with cirrhosis, those who maintained a virologic response were significantly less likely than those with viral breakthrough to develop worsening disease or hepatocellular carcinoma. Survival was significantly better in patients with Child-Pugh class A cirrhosis at baseline who maintained a virologic response. Similar observations were described in another report of 651 patients with advanced fibrosis or cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that there are substantial clinical benefits in patients with HBeAg-negative chronic HBV who maintain a virologic response. However, only 39 percent of patients achieve such a response after four years of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INTERFERON NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    appears to have similar efficacy in patients who failed to respond to interferon compared with treatment naive patients. One of the largest studies to address this population focused on 238 HBeAg-positive patients who were randomly assigned to one of three regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      (100 mg PO once daily) for 52 weeks",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      (100 mg PO once daily) for eight weeks followed by lamivudine (100 mg PO once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      (10 million units SQ three times weekly) for an additional 16 weeks",
"     </li>",
"     <li>",
"      Placebo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normalization of serum alanine aminotransferase (ALT) was observed significantly more often with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      compared with placebo or combination therapy (44 versus 15 and 18 percent, respectively).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      -resistant",
"      <span class=\"nowrap\">",
"       rtM204V/I",
"      </span>",
"      mutations developed in 27 percent of the lamivudine patients compared to none in the placebo or combination therapy groups.",
"     </li>",
"     <li>",
"      HBeAg seroconversion occurred in a similar proportion of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , placebo and combination groups (18, 13, and 12 percent).",
"     </li>",
"     <li>",
"      HBeAg loss occurred significantly more often in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      group compared with placebo or combination groups (33 versus 13 and 21 percent respectively).",
"     </li>",
"     <li>",
"      A histologic response (defined as a two-point reduction in the HAI) was more likely with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      compared with placebo or combination therapy (52 versus 25, and 32 percent, respectively). It should be emphasized that the second biopsy was performed during treatment in the lamivudine group and 28 weeks after stopping treatment in the other two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in children with chronic hepatitis B is limited. Available data indicate that lamivudine is safe and effective in children but the benefit must be carefully balanced against the risk of selecting resistant mutants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link\">",
"     \"Overview of hepatitis B virus infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EFFECT ON LIVER HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, one-year treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is associated with histologic improvement in more than 50 percent of patients. As expected, the observed improvement after a short course of lamivudine was predominantly a reduction in necroinflammation. Longer duration of treatment also appears to reduce fibrosis.",
"   </p>",
"   <p>",
"    This was illustrated in a study of 63 patients who had three liver biopsies at baseline, at the end of one year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment as part of a controlled trial, and after two additional years of open label treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/16\">",
"     16",
"    </a>",
"    ]. At the end of one year, 36 patients (57 percent) showed a &ge;2 point improvement in the Histologic Activity Index. After two additional years of treatment, 60 percent remained stable while 19 percent continued to improve. Compared to baseline, 77 percent of patients with no lamivudine-resistant mutations showed improvement, 18 percent had no change, and 5 percent had worsening of necroinflammatory activity after three years of lamivudine treatment, while the corresponding values for patients with lamivudine resistant mutations were 45, 41, and 14 percent, respectively. Fibrosis improved in 12 of 19 patients (63 percent) while cirrhosis improved in 8 of 11 patients (73 percent). These data support the beneficial effect of three-year lamivudine treatment on liver histology, but the emergence of lamivudine-resistant mutations blunted the histologic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DURABILITY OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial data suggested that patients who achieve HBeAg seroconversion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment are likely to have a durable response. Follow-up of patients enrolled in various clinical trials in the United States and Europe reported that 30 of 39 (77 percent) patients with HBeAg seroconversion had durable response after a median follow-up of 37 months (range 5 to 46 months). In addition, 8 (20 percent) patients developed HBsAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/17\">",
"     17",
"    </a>",
"    ]. The estimated durability of lamivudine-induced HBeAg seroconversion was lower, 64 percent at 36 months, if patients who relapsed prior to entry into the long-term follow-up were included.",
"   </p>",
"   <p>",
"    Three studies from Asia reported lower rates of durable response, 38 to 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The duration of treatment after HBeAg seroconversion appeared to be important in maintaining durable response as the median duration of treatment was shorter in patients who did not have a durable response (9 versus 20 months), an observation that has also been suggested in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/21\">",
"     21",
"    </a>",
"    ]. Another study from Taiwan found that durability of response was increased among patients infected with HBV genotype B versus C, those below the age of &le;36 years, and those who had &gt;eight months additional treatment after HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The durability of response with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    may be less than for interferon. This issue was addressed in an analysis of individual patient data that included a total of 130 patients from 24 centers who achieved HBeAg seroconversion following treatment with lamivudine (n = 59), interferon (n = 49), or combination therapy with interferon plus lamivudine (n = 22) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/23\">",
"     23",
"    </a>",
"    ]. The three-year cumulative rate of HBeAg relapse was significantly higher with lamivudine monotherapy compared with interferon alone or combination therapy (54 versus 32 and 23 percent, respectively). However, there were significant baseline differences among the three treatment groups and it is unclear if consecutive patients with treatment response in those 24 centers were included in the analysis.",
"   </p>",
"   <p>",
"    The durability of response in patients with HBeAg-negative chronic hepatitis B (defined as normal alanine aminotransferase [ALT] and undetectable serum HBV DNA using non-PCR assays) who stopped treatment after one year is lower. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'HBeAg-negative chronic hepatitis B'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A problem with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment is the development of drug resistance. Genotypic analysis of viral isolates from patients with virologic breakthrough while receiving lamivudine suggests that the principal mutation associated with resistance is a methionine to valine or isoleucine substitution -",
"    <span class=\"nowrap\">",
"     rtM204V/I",
"    </span>",
"    in the YMDD motif of the catalytic domain of HBV polymerase. Another mutation results in a leucine to methionine substitution (at position rtL180M) located upstream of the YMDD motif [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/24\">",
"     24",
"    </a>",
"    ]. The latter mutation is always found in combination with one of the mutations in the YMDD motif and appears to be a compensatory mutation that restores replication fitness of the virus. In vitro studies have demonstrated that the",
"    <span class=\"nowrap\">",
"     rtM204V/I",
"    </span>",
"    mutations confer up to 10,000-fold resistance, suggesting that antiviral response cannot be restored by increasing the dose of lamivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/25\">",
"     25",
"    </a>",
"    ]. Resistance may also be a result of a substitution of valine or threonine for alanine at position 181",
"    <span class=\"nowrap\">",
"     (rtA181V/T).",
"    </span>",
"   </p>",
"   <p>",
"    Resistance",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    due to the",
"    <span class=\"nowrap\">",
"     rtM204V/I",
"    </span>",
"    mutants was detected in 81 of 335 patients with HBeAg-positive chronic hepatitis B (24 percent) treated in the clinical trials mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/6,26,27\">",
"     6,26,27",
"    </a>",
"    ]. The incidence of",
"    <span class=\"nowrap\">",
"     rtM204V/I",
"    </span>",
"    mutations increased with longer duration of therapy (10 percent at 24 weeks, 24 percent at 52 weeks, and up to 65 percent by five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/28\">",
"     28",
"    </a>",
"    ]. The development of resistance should be suspected in patients who have a breakthrough infection, defined as &gt;1 log or 10-fold increase in serum HBV DNA from nadir. Breakthrough infection can also occur due to non-compliance. Breakthrough due to non-compliance is associated with reappearance of wild type HBV, and has been shown to respond to reinstitution of therapy.",
"   </p>",
"   <p>",
"    Several studies showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil, a nucleotide analogue, is effective in inhibiting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV mutants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    , a nucleotide analogue, is also effective in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     HBeAg-negative chronic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant mutants have also been reported in 57 to 64 percent of patients treated for HBeAg-negative chronic hepatitis B for more than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/7-11,29,30\">",
"     7-11,29,30",
"    </a>",
"    ]. One study included 44 consecutive patients with cirrhosis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    100 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/30\">",
"     30",
"    </a>",
"    ]. After five years, 21 (48 percent) maintained undetectable serum HBV DNA levels (by non PCR methods) and a normal ALT while 22 (52 percent) developed lamivudine resistance. Only 10 percent of patients had undetectable HBV DNA levels by PCR. The five-year cumulative probability for developing resistance was estimated to be 63 percent. Clinical deterioration developed in none of the responders compared with seven (32 percent) nonresponders. Overall, liver related complications occurred less frequently in responders than those with resistance (28 versus 64 percent).",
"   </p>",
"   <p>",
"    In another series of 29 patients, the cumulative rate of detection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistant mutations after one and two years was 10 and 56 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/29\">",
"     29",
"    </a>",
"    ]. Interestingly, three patients who developed lamivudine-resistant mutants had reversion of the precore stop codon mutation, which was associated with the reappearance of HBeAg in two of the patients. Reversion from stop codon to wild type sequence in the precore region in association with the emergence of lamivudine-resistant mutants was also reported in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virologic breakthrough appears ultimately to lead to a biochemical relapse. In one report, biochemical relapse developed within 24 months in all patients who had virologic breakthrough [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Predictors of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors predicting the development of resistant mutants were analyzed in a study involving 159 Chinese patients who had undergone treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    as part of three clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/33\">",
"     33",
"    </a>",
"    ]. Pretreatment HBV DNA and serum ALT levels correlated inversely with the time to HBV DNA breakthrough with lamivudine-resistant mutants. Patients with HBV DNA levels more than 10(3)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    after six months of therapy had a 63 percent chance of subsequently developing lamivudine-resistant mutation during a median 30-month follow-up (compared with a 13 percent chance if they were below this level).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Long-term significance of rtM204V/I mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term clinical significance of patients with",
"    <span class=\"nowrap\">",
"     rtM204V/I",
"    </span>",
"    mutations is generally worse than those with maintained virus suppression, although the initial clinical manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistance are variable. The following observations have been made:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     HBV DNA and ALT levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, serum HBV DNA and ALT levels remain lower than pretreatment values initially, suggesting that there may be a continued suppressive effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    on wild type virus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/27,34\">",
"     27,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The beneficial effects of continued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment in patients with resistant mutants are related to the impaired replication capacity of the mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This accounts for the low serum HBV DNA levels in patients with resistant mutations, and the rapid outgrowth of the wild type virus upon withdrawal of lamivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the initial benefits are negated with time [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/17,32\">",
"     17,32",
"    </a>",
"    ], possibly due to selection for additional mutations that may restore replication fitness of HBV and hence increase hepatic necroinflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hepatitis flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis flares, hepatic decompensation and deaths have been described in patients who developed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance. Patients with underlying cirrhosis and those who are immunosuppressed are more prone to develop hepatic decompensation, when they develop breakthrough infection. Hepatitis flares can develop in patients who continue on treatment after developing resistance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      -resistant mutations&nbsp;who continued on treatment &mdash; One of the largest studies with the longest follow-up included 998 patients with HBeAg positive compensated chronic HBV who received lamivudine for up to six years (median four years) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/28\">",
"       28",
"      </a>",
"      ]. Hepatitis flares occurred in 10 percent of patients in year one, and in 18 to 21 percent of patients in years two to five. Lamivudine resistance increased from 23 percent in year one to 65 percent in year five. During each year, hepatitis flares occurred more commonly in those with lamivudine resistant mutations. Furthermore, the association between development of hepatitis flares and development of lamivudine resistance increased over time (from 43 percent in year one to &gt;80 percent in year three). Among patients with lamivudine resistance, occurrence of substantial biochemical changes (increase in bilirubin and INR) remained stable for up to five years while occurrence of hepatic decompensation increased significantly in patients with lamivudine resistance for more than four years (from 0-2 to 6 percent).",
"      <br/>",
"      <br/>",
"      In some patients, the hepatitis flare may be associated with HBeAg seroconversion. In the report above, for example [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/28\">",
"       28",
"      </a>",
"      ], HBeAg seroconversion occurred within six months of ALT elevation in 7 to 23 percent of patients during the course of the study (compared with 16 percent of patients who had received placebo during the first year). Another series included 55 patients with HBeAg positive chronic hepatitis B who received lamivudine continuously for a minimum of two years. Thirty-two (58 percent) patients developed lamivudine-resistant mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/38\">",
"       38",
"      </a>",
"      ]. An acute exacerbation of hepatitis was observed in 13 patients (40 percent) between 4 and 94 weeks (median 24 weeks) after the emergence of the mutant, an incidence that was much higher than that observed in patients without the mutant during the same interval (4 percent). Of 12 evaluable patients with an acute exacerbation, eight (75 percent) developed HBeAg seroconversion; three of these eight patients had transient hepatic decompensation. None of 19 patients without exacerbation had HBeAg seroconversion.",
"      <br/>",
"      <br/>",
"      Similar findings have been reported in patients with HBeAg-negative chronic hepatitis B.",
"     </li>",
"     <li>",
"      Patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      -resistant&nbsp;mutations who stopped treatment &mdash; Cessation of treatment in patients with breakthrough infection may result in a flare of the liver disease and, rarely, liver failure, possibly due to uncontrolled replication of wild type virus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Whether flares are more likely when",
"      <strong>",
"      </strong>",
"      therapy is stopped versus continued after development of resistance is uncertain since studies have reached disparate conclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. As a general rule, rescue therapy with antiviral drugs such as the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      or switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      is preferred, and withdrawal of lamivudine is not advised.",
"     </li>",
"     <li>",
"      Patients without",
"      <span class=\"nowrap\">",
"       M204V/I",
"      </span>",
"      mutations &mdash; Flares of hepatitis have also been reported even if a",
"      <span class=\"nowrap\">",
"       M204V/I",
"      </span>",
"      mutation is not detected. This was illustrated in a report that included 41 patients in whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      was discontinued after at least three months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/42\">",
"       42",
"      </a>",
"      ]. An acute flare of hepatitis was observed in seven patients (17 percent), two of whom (5 percent) developed jaundice and incipient liver failure. A",
"      <span class=\"nowrap\">",
"       M204V/I",
"      </span>",
"      mutation was observed in only one of these patients prior to lamivudine withdrawal. All hepatitis flares were associated with wild type virus. Lamivudine was reintroduced in the two patients who developed jaundice, both of whom recovered and achieved HBeAg seroconversion within two months. These observations highlight the importance of close monitoring of patients after discontinuation of lamivudine, particularly if treatment is withdrawn prior to HBeAg seroconversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Additional mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have reported emergence of additional mutations in the polymerase gene (rtL180M, rtV173L &ndash; valine to isoleucine substitution and changes at rt80) during long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/29,43\">",
"     29,43",
"    </a>",
"    ]. In vitro studies indicate that they represent compensatory mutations that will restore the replication fitness of the",
"    <span class=\"nowrap\">",
"     rtM204V/I",
"    </span>",
"    mutant. However, the",
"    <span class=\"nowrap\">",
"     rtA181V/T",
"    </span>",
"    mutation is considered a primary mutation and is associated with decreased susceptibility to lamivudine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Effect on liver histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies showed that histologic improvement after the first year of therapy is negated in some patients who subsequently developed breakthrough infection due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREDICTORS OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment alanine aminotransferase (ALT) levels have consistently been the most important predictor of response after one year of therapy. This was supported in a pooled analysis from four",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/6,45-47\">",
"     6,45-47",
"    </a>",
"    ] that included a total of 406 patients who received lamivudine 100 mg daily for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/48\">",
"     48",
"    </a>",
"    ]. The only two independent predictors of response identified on multivariate analysis were elevated baseline ALT levels and a higher Histologic Activity Score. The rates of HBeAg seroconversion (ie, loss of detectable levels of HBeAg and HBV DNA in serum and the appearance of antibody to HBeAg) for patients with pretreatment ALT levels within normal, one to two times normal, two to five times normal, and more than five times normal were 2, 7, 20, and 42 percent, respectively (",
"    <a class=\"graphic graphic_table graphicRef57652 \" href=\"UTD.htm?22/50/23340\">",
"     table 1",
"    </a>",
"    ). The corresponding figures for 196 patients in the placebo group were 0, 5, 9, and 15 percent, respectively. These variables were predictive of lamivudine response in both Asian and Caucasian patients.",
"   </p>",
"   <p>",
"    At least one report found that HBV DNA levels during the first 4 to 24 weeks of therapy predicted response with long-term treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/49\">",
"     49",
"    </a>",
"    ]. The study included 74 HBeAg positive patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    for up to five years. During follow-up, 17 patients were considered to have achieved an ideal response (HBV DNA &lt;200",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     IU/mL),",
"    </span>",
"    HBeAg seroconversion, normal ALT levels and absence of resistant mutations). A reduction of HBV DNA levels of 4 and 3.6 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (2000 and 800",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    at weeks 4 and 16, respectively, predicted an ideal response. Patients with HBV DNA levels above these cutoffs had an 84 and 88 percent chance, respectively, of",
"    <strong>",
"     not",
"    </strong>",
"    achieving an ideal response at five years. The authors concluded that measurement of HBV DNA levels at week 4 should be performed and alternative treatments should be considered in those with a decrease in HBV DNA of less than a 4 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (2000",
"    <span class=\"nowrap\">",
"     IU/mL).",
"    </span>",
"    However, these data were based on post hoc analysis of data from a very small number of patients. Furthermore, timing for assessment of initial response may be different for other",
"    <span class=\"nowrap\">",
"     nucleoside/tide",
"    </span>",
"    analogues and for patients with HBeAg-negative chronic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is usually well tolerated. Potentially serious, but uncommon, adverse effects include pancreatitis and lactic acidosis while on therapy. As discussed above, patients who develop lamivudine resistance may experience a flare in disease activity with the emergence of the resistant mutants or after withdrawal of therapy. Flares can be associated with hepatic decompensation in those with advanced liver disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    appears to have a favorable safety profile even with long-term treatment. One of the largest studies with the longest follow-up included 998 patients with HBeAg positive compensated chronic HBV who received lamivudine for up to six years (median four years) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/28\">",
"     28",
"    </a>",
"    ]. As discussed above, hepatitis flares occurred in 10 percent of patients in year one, and in 18 to 21 percent of patients in years two to five. There were ten episodes of hepatic decompensation in eight patients (1 percent). Fifty-three patients (5 percent) experienced a total of 60 liver-disease related serious adverse events including two deaths. The authors concluded that lamivudine treatment for up to six years has an excellent safety profile in patients with HBeAg-positive compensated liver disease but that patients with longstanding lamivudine-resistant mutations may experience worsening of liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DURATION AND ENDPOINTS OF THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     HBeAg positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HBeAg positive chronic hepatitis B, the endpoint of treatment is HBeAg seroconversion. It is reasonable to check HBV DNA levels every three months to monitor for antiviral response and breakthrough infection, and to check HBeAg and anti-HBe at 12 months and every three to six months thereafter to assess for HBeAg seroconversion.",
"   </p>",
"   <p>",
"    Relapse rates upon discontinuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    after HBeAg seroconversion have been reported to be more than 50 percent; however, some studies included a small number of patients and some included no or limited duration of consolidation therapy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Durability of response'",
"    </a>",
"    above.) Several patient and treatment-related factors have been associated with the likelihood of a durable response as described above. Limited data suggest that extending treatment for at least 12 months after HBeAg seroconversion may increase the durability of the response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/20,22,50\">",
"     20,22,50",
"    </a>",
"    ]. A study of 178 patients who discontinued lamivudine after achieving HBeAg loss and undetectable serum HBV DNA found that the rate of relapse (defined as redetection of HBV DNA in serum) increased from 16 percent at one year to 30 percent at five years. Age &le;40 years and additional treatment for more than 12 months after HBeAg loss or seroconversion were independent factors for sustained virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/50\">",
"     50",
"    </a>",
"    ]. In this study, the five-year cumulative rate of virologic relapse was 9 percent in patients who continued treatment for at least 12 months after HBeAg seroconversion compared with 62 percent in patients who had no or a shorter duration of consolidation therapy.",
"   </p>",
"   <p>",
"    Some authorities have advocated continuing therapy indefinitely; one study found that compared with those in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    was stopped, continuing lamivudine after HBeAg seroconversion was associated with a higher proportion of patients continuing to have undetectable HBV DNA, a reduced number of alanine aminotransferase (ALT) flares, and low rates of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/51\">",
"     51",
"    </a>",
"    ]. Given the high rate of resistance associated with prolonged lamivudine treatment, switching to",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogs with a higher genetic barrier to resistance (lower risk of drug resistance) might be considered if treatment is to be continued indefinitely.",
"   </p>",
"   <p>",
"    Based upon the available data, discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    can be considered in patients who have confirmed HBeAg seroconversion (HBeAg negative and anti-HBe positive on two occasions with undetectable HBV DNA) and at least 12 additional months of therapy after HBeAg seroconversion has been confirmed on repeat testing. Patients who stopped treatment must be closely monitored for relapse so treatment can be reinstituted if necessary.",
"   </p>",
"   <p>",
"    In patients who have not achieved HBeAg seroconversion after one year of therapy, treatment may be continued with the hope that it will result in HBeAg seroconversion in subsequent years, but these patients should be switched to",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogs with a higher genetic barrier to resistance.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    might be a better option than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    in patients who have been exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . As an alternative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    can be added in countries where tenofovir is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     HBeAg-negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The end-point of treatment of HBeAg-negative chronic hepatitis B has not been defined. Relapse appears to be common even after suppression of serum HBV DNA to levels that are not detectable by PCR assays. Thus, it is not clear what the optimal duration of therapy is and when treatment can be stopped. Extending treatment beyond one year, however, is associated with diminishing rate of sustained biochemical and virological response due to selection of resistant mutants.",
"   </p>",
"   <p>",
"    On the other hand, a subset of patients appears to have lasting viral suppression. One of the largest series to focus on such responders included 191 patients with chronic HBeAg-negative HBV who achieved sustained virologic suppression for at least five years while receiving continuous monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/52\">",
"     52",
"    </a>",
"    ]. They were then followed for a median of 36 months. The virologic response was maintained in 67 percent, while HBsAg clearance was observed in 12 percent. Virologic breakthrough was observed in one-third of patients due to the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistant mutations. These observations suggest that long-term monotherapy is effective in a subset of patients who had undetectable HBV DNA after many years of lamivudine treatment but that virologic breakthrough can still occur, requiring careful monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of myelotoxicity and the infrequent occurrence of serum alanine aminotransferase (ALT) flares during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment led to clinical trials in patients with advanced disease including those with decompensated cirrhosis or recurrent hepatitis B after liver transplantation, conditions in which interferon is ineffective and contraindicated.",
"   </p>",
"   <p>",
"    A study of patients with bridging fibrosis or compensated cirrhosis suggested that treatment may slow the rate of disease progression and decrease the incidence of hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/14\">",
"     14",
"    </a>",
"    ]. The study included 651 patients (Ishak fibrosis stages 4 to 6) who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or placebo; the study was terminated after a median of 32 months because of significantly fewer endpoints in the lamivudine group.",
"   </p>",
"   <p>",
"    The primary endpoint was time to disease progression defined as an increase in the Child-Pugh score of &ge;2 or the development of hepatocellular carcinoma, spontaneous bacterial peritonitis, variceal bleeding, or liver-related death. Disease progression was significantly reduced in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    group (8 versus 18 percent, Hazard Ratio 0.45, 95% CI 0.28-0.73). The Child-Pugh score increased in 3.4 percent of patients receiving lamivudine compared with 8.8 percent of those receiving placebo while hepatocellular carcinoma occurred in 3.9 percent of those in the lamivudine group compared with 7.4 percent in those in the placebo group. Lamivudine-resistant mutations developed in 49 percent of patients receiving lamivudine. Such patients were more likely to experience an increase in the Child-Pugh score compared with those in whom a mutation did not develop (7 versus &lt;1 percent), the presence of resistant mutations did not negate the overall benefit of lamivudine but the duration of follow-up was short.",
"   </p>",
"   <p>",
"    Similarly, studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in patients with decompensated cirrhosis have generally shown that lamivudine treatment is associated with improvement in liver function and clinical status in 60 to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/53-62\">",
"     53-62",
"    </a>",
"    ]. However, clinical improvement is gradual (occurring over three to six months), suggesting that lamivudine may not be able to reduce mortality or the need for liver transplantation in patients with advanced liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/59\">",
"     59",
"    </a>",
"    ]. This conclusion was supported by a National Institutes of Health funded retrospective study that summarized outcomes of 309 patients (from 20 North American centers) with chronic HBV who were awaiting liver transplantation, of whom 162 had been treated with lamivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/58\">",
"     58",
"    </a>",
"    ]. Lamivudine treatment was not associated with improvement in pre-liver transplant or liver transplant-free survival. However, liver disease severity improved in a subset of patients.",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (or other nucleoside analogues) should be administered to all patients with compensated cirrhosis to prevent adverse clinical outcome remains to be determined. The multi-center Asian trial enrolled only patients who were HBeAg positive or had serum HBV DNA levels &gt;700,000 genome",
"    <span class=\"nowrap\">",
"     equivalents/ml;",
"    </span>",
"    whether patients with low viral level will benefit is unclear. Current guidelines recommend that patients with compensated cirrhosis and serum HBV DNA levels more than 2,000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    should receive antiviral treatment.",
"    <span class=\"nowrap\">",
"     Nucleos/tide",
"    </span>",
"    analogs with a lower risk of drug resistance, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , are preferred since most patients will continue treatment for years, if not for life.",
"   </p>",
"   <p>",
"    For patients with decompensated cirrhosis, the benefit may be greatest in those who present with Child's class B cirrhosis. Clinical improvement may not occur fast enough for patients with Child-Pugh class C cirrhosis or high Model for End-stage Liver Disease (MELD) score and liver transplantation is often needed for such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, in our clinical experience, the patients most likely to benefit were those who developed acute decompensation due to recent flares in disease activity, particularly if treatment is initiated early [",
"    <a class=\"abstract\" href=\"UTD.htm?6/24/6538/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major concern with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment is development of resistant mutants, particularly in patients with cirrhosis, who likely need long-term treatment and who may decompensate when breakthrough infection occurs. Based upon the available data, many transplant centers agree that patients with decompensated cirrhosis and detectable serum HBV DNA level should be placed on antiviral therapy. With the availability of newer therapies that have lower rates of drug resistance, lamivudine is not recommended as a first line treatment in these patients. Therapy of patients with decompensated cirrhosis should be coordinated with a liver transplant team.",
"   </p>",
"   <p>",
"    The multi-center Asian trial in patients with compensated cirrhosis found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    led to a significant reduction in HCC development, but when the prevalent HCC cases were excluded, the difference was not significant. Other studies in patients with decompensated cirrhosis reported that HCC can occur in patients who have improved or stabilized liver disease and continued viral suppression. Therefore, the risk of HCC is not eliminated and long-term monitoring is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to hepatitis B virus (HBV) is common in patients with HIV infection, particularly in homosexual men and those with a history of injection drug use. Hepatitis B surface and core antibodies have been found in 65 to 96 percent of these high-risk groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .) Chronic HBV affects approximately 10 percent of HIV-infected patients worldwide. Initial treatment of HBV and HIV coinfected patients depends on the need to suppress one or both viruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in the transplant setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     WITH IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to hepatitis B virus (HBV) reactivation with immunosuppression and the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    for prophylaxis and treatment are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    given in combination with other treatments is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Choice of antiviral agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to use a specific antiviral agent as primary therapy should be made jointly by the clinician and patient. The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    as primary therapy has diminished with the availability of",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogues that are associated with a lower rate of resistance.",
"   </p>",
"   <p>",
"    An advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is its lower cost but the costs of subsequent rescue therapy may outweigh that of the lower upfront cost of lamivudine as a first-line therapy. The main setting for using lamivudine is in patients with a short anticipated duration of treatment and low pretreatment serum HBV DNA. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"     \"Patient information: Hepatitis B (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Dose, duration and endpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    should be administered orally in doses of 100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Dose reduction is necessary in patients with renal insufficiency (creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Duration and endpoints of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Higher dose, 150 mg twice daily, in combination with other retroviral therapy is needed in patients with HBV and HIV coinfection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Patients who develop resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salvage treatment with agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which are effective against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant mutants, should be initiated as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    -resistant HBV is less susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , and presence of",
"    <span class=\"nowrap\">",
"     rtM204V/I",
"    </span>",
"    mutation diminishes the barrier to entecavir resistance. Therefore, entecavir is not an optimal treatment for lamivudine-refractory HBV.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is preferred because it has more potent antiviral activity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Resistance'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Tenofovir'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/1\">",
"      Severini A, Liu XY, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1995; 39:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/2\">",
"      Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/3\">",
"      Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/4\">",
"      Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/5\">",
"      Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001; 120:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/6\">",
"      Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/7\">",
"      Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/8\">",
"      Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/9\">",
"      Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/10\">",
"      Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002; 66:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/11\">",
"      Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001; 8:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/12\">",
"      Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/13\">",
"      Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/14\">",
"      Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/15\">",
"      Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/16\">",
"      Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/17\">",
"      Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/18\">",
"      Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/19\">",
"      Leung NW, Liaw YF, Chang TT, et al. Durable HBeAg response in Chinese patients treated with lamivudine (abstract). Hepatology 2001; 34:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/20\">",
"      Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/21\">",
"      Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/22\">",
"      Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/23\">",
"      van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/24\">",
"      Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/25\">",
"      Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/26\">",
"      Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/27\">",
"      Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/28\">",
"      Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/29\">",
"      Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/30\">",
"      Lampertico P, Vigano M, Iavarone M, et al. The long-term outcome of HBeAg-negative patients with cirrhosis treated with lamivudine monotherapy: a 5-year prospective cohort study (abstract). J Hepatol 2004; 40 (Suppl 1):16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/31\">",
"      Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/32\">",
"      Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/33\">",
"      Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/34\">",
"      Atkins M, Hunt CM, Brown N, et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients (abstract). Hepatology 1998; 28:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/35\">",
"      Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/36\">",
"      Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999; 29:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/37\">",
"      Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/38\">",
"      Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/39\">",
"      Honkoop P, Niesters HG, de Man RA, et al. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/40\">",
"      Chen CH, Lee CM, Lu SN, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004; 41:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/41\">",
"      Liaw YF, Chien RN, Yeh CT, et al. No benefit to continue lamivudine therapy after emergence of YMDD mutations (abstract). Hepatology 2004; 9:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/42\">",
"      Honkoop P, de Man RA, Niesters HG, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/43\">",
"      Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/44\">",
"      Leung NW, Lai CL, Guan R, Liaw YF. The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years of lamivudine therapy in Chinese patients (abstract). Hepatology 2001; 34:348A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/45\">",
"      Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/46\">",
"      Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/47\">",
"      Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology 1998; 28:388A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/48\">",
"      Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/49\">",
"      Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/50\">",
"      Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010; 51:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/51\">",
"      Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009; 104:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/52\">",
"      Fasano M, Lampertico P, Marzano A, et al. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012; 56:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/53\">",
"      Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/54\">",
"      Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/55\">",
"      Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/56\">",
"      Perrillo RP, Schiff ER, Dienstag JL, et al. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B (abstract). Hepatology 1999; 30:301A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/57\">",
"      Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000; 6:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/58\">",
"      Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/59\">",
"      Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/60\">",
"      Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/61\">",
"      Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/62\">",
"      Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/24/6538/abstract/63\">",
"      Fontana RJ, Lok AS. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol 2000; 33:329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3632 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-A161942C46-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6538=[""].join("\n");
var outline_f6_24_6538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HBeAg-positive chronic hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Asian patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HBeAg-negative chronic hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INTERFERON NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EFFECT ON LIVER HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DURABILITY OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HBeAg-negative chronic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Predictors of resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Long-term significance of rtM204V/I mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - HBV DNA and ALT levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hepatitis flares",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Additional mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Effect on liver histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREDICTORS OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DURATION AND ENDPOINTS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HBeAg positive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HBeAg-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      WITH IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Choice of antiviral agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Dose, duration and endpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Patients who develop resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/50/23340\" title=\"table 1\">",
"      Predictors response lamivudine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_24_6539="Prednisone insulin";
var content_f6_24_6539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blood glucose concentrations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time of day",
"       </td>",
"       <td class=\"subtitle1\">",
"        Before start of prednisone",
"       </td>",
"       <td class=\"subtitle1\">",
"        After start of prednisone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Before breakfast",
"       </td>",
"       <td>",
"        77 to 119",
"       </td>",
"       <td>",
"        93 to 138",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Before lunch",
"       </td>",
"       <td>",
"        95 to 136",
"       </td>",
"       <td>",
"        191 to 349",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Before supper",
"       </td>",
"       <td>",
"        105 to 141",
"       </td>",
"       <td>",
"        197 to 269",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bedtime",
"       </td>",
"       <td>",
"        116 to 156",
"       </td>",
"       <td>",
"        151 to 253",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lloyd Axelrod, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6539=[""].join("\n");
var outline_f6_24_6539=null;
var title_f6_24_6540="Medications associated with fever";
var content_f6_24_6540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications associated with fever",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cephalosporins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoroquinolones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrofurantoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiazide diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furosemide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spironolactone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydralazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procainamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha methyldopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anticonvulsants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heparin (especially unfractionated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal antiinflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunoglobulins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propylthiouracil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyurea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycophenolate mofetil",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6540=[""].join("\n");
var outline_f6_24_6540=null;
var title_f6_24_6541="Lead chelating agents A";
var content_f6_24_6541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59995%7EPEDS%2F71832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59995%7EPEDS%2F71832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chelating agents used in the treatment of childhood lead poisoning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Product name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chemical name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abbreviation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium disodium versenate",
"       </td>",
"       <td>",
"        Edetate disodium calcium",
"       </td>",
"       <td>",
"        Calcium disodium ethylenediamine-tetracetate",
"       </td>",
"       <td>",
"        CaNa",
"        <sub>",
"         2",
"        </sub>",
"        EDTA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BAL* in oil",
"       </td>",
"       <td>",
"        Dimercaprol",
"       </td>",
"       <td>",
"        2,3-dimercapto-propanol",
"       </td>",
"       <td>",
"        BAL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cuprimine",
"       </td>",
"       <td>",
"        D-penicillamine",
"       </td>",
"       <td>",
"        3-merecapto-d-valine",
"       </td>",
"       <td>",
"        D-penicillamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemet",
"       </td>",
"       <td>",
"        Succimer",
"       </td>",
"       <td>",
"        Meso -2,3-dimercapto- succinic acid",
"       </td>",
"       <td>",
"        DMSA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * British anti-Lewisite.",
"    </div>",
"    <div class=\"reference\">",
"     www.atsdr.cdc.gov/csem/lead/pbmanage_therapy2.html",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristic features and adverse effects of chelating agents used in the treatment of childhood lead poisoning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        CaNa",
"        <sub>",
"         2",
"        </sub>",
"        EDTA",
"       </td>",
"       <td>",
"        Only removes lead from the extracellular compartment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May increase CNS lead burden",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Must be given after BAL has been administered in patients with severe lead intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause hypercalcemia, renal dysfunction, excretion of divalent minerals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        BAL*",
"       </td>",
"       <td>",
"        Must be administered intramuscularly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be administered in the presence of renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contraindicated in individuals with peanut allergy or hepatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause hemolysis in individuals with G6PD deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Causes vomiting if administered with iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        D-penicillamine",
"       </td>",
"       <td>",
"        Not FDA approved for treatment of lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administered orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absorption impaired by iron, antacids, and food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contraindicated in penicillin allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid giving with dairy products or iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause rash, nausea, vomiting, leukopenia, thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        DMSA",
"       </td>",
"       <td>",
"        FDA approved for treatment of lead poisoning in children with BLL &gt;45 &micro;g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administered orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause elevated LFT's",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause hemolysis in individuals with G6PD deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * British anti-Lewisite.",
"    </div>",
"    <div class=\"reference\">",
"     file://www.atsdr.cdc.gov/HEC/CSEM/lead/treatment_management.html#Table2",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6541=[""].join("\n");
var outline_f6_24_6541=null;
var title_f6_24_6542="Site of recurrence";
var content_f6_24_6542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Location of local recurrence after breast-conserving surgery with or without postoperative radiation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Investigator",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of local recurrences occurring at or near lumpectomy site*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of patients with elsewhere local recurrence&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        With radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fourquet et al",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        1989",
"       </td>",
"       <td>",
"        518",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boyages et al",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        1990",
"       </td>",
"       <td>",
"        783",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kurtz et al",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        1990",
"       </td>",
"       <td>",
"        1593",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fowble et al",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        1990",
"       </td>",
"       <td>",
"        1093",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clark et al",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        416",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gage et al",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        1995",
"       </td>",
"       <td>",
"        974",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liljegren et al",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        5.0&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Touboul et al",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        528",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Smith et al",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        1152",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Veronesi et al",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        2001",
"       </td>",
"       <td>",
"        299",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Huang et al",
"        <sup>",
"         [11]",
"        </sup>",
"       </td>",
"       <td>",
"        2002",
"       </td>",
"       <td>",
"        1339",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Without radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clark et al",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        421",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liljegren et al",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        5.0&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Veronesi et al",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        2001",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Total",
"       </td>",
"       <td>",
"        <strong>",
"         9764",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         71",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.3",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Number of local recurrences at or near prior lumpectomy site/total number of local recurrences.",
"     <br>",
"      &bull; Number of recurrences outside area of prior lumpectomy site/total number of patients treated.",
"      <br>",
"       &Delta; Percentages reported represent numbers from total series.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989; 17:719.",
"       </li>",
"       <li>",
"        Boyages J, Recht A, Connolly JL, et al. Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. Radiother Oncol 1990; 19:29.",
"       </li>",
"       <li>",
"        Kurtz JM, Spitalier JM, Amalric R, et al. The prognostic significance of late local recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys 1990; 18:87.",
"       </li>",
"       <li>",
"        Fowble B, Solin LJ, Schultz DJ, et al. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys 1990; 19:833.",
"       </li>",
"       <li>",
"        Clark RM, McCulloch PB, Levine MN, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 1992; 84:683.",
"       </li>",
"       <li>",
"        Gage I, Recht A, Gelman R, et al. Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1995; 33:245.",
"       </li>",
"       <li>",
"        Liljegren G, Holmberg L, Bergh J, et al. 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol 1999; 17:2326.",
"       </li>",
"       <li>",
"        Touboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1999; 43:25.",
"       </li>",
"       <li>",
"        Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 2000; 48:1281.",
"       </li>",
"       <li>",
"        Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 2001; 12:997.",
"       </li>",
"       <li>",
"        Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 2002; 95:2059.",
"       </li>",
"      </ol>",
"      Reproduced with permission from: Kuerer HM, Julian TB, Strom EA, et al. Accelerated partial breast radiation after conservative surgery for breast cancer. Ann Surg 2004; 239:338. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6542=[""].join("\n");
var outline_f6_24_6542=null;
var title_f6_24_6543="IVP megaureter";
var content_f6_24_6543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravenous pyelogram of bilateral congenital megaureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravenous pyelogram of a congenital nonrefluxing nonobstructive megaureter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_24_6543=[""].join("\n");
var outline_f6_24_6543=null;
